NICE recommends once-weekly Sogroya®▼ (somapacitan injection) as treatment for growth failure caused by growth hormone deficiency in people aged 3 to 17 years

·         It is estimated that 1 in 3,500-4,000 children in the UK live with growth hormone deficiency[1]

Gatwick, UK, June 3 2025 – Novo Nordisk has announced that Sogroya^® (somapacitan injection) has been recommended by the National Institute for Health and Care Excellence (NICE) as a treatment for people aged 3 to 17 years with paediatric growth hormone deficiency.  

The treatment is used as a once-weekly replacement of endogenous growth hormone (GH) in people 3 to 17 years with growth failure due to growth hormone deficiency (paediatric GHD).

For the majority of people, growth hormone is produced naturally by the pituitary gland in the brain. As its name implies, growth hormone is essential for growth in childhood.[2]

In the UK there are an estimated 1 in 3,500-4,000 children living with growth hormone deficiency, where their body is deficient in growth hormone.[3]

“We believe the launch of Sogroya^® will help provide an additional option to support people living with growth hormone deficiencies in the UK and look forward to working with healthcare providers to achieve this,” said Sebnem Avsar Tuna, General Manager of Novo Nordisk UK.